Author + information
- Nathan Goldstein, MD* (, )
- Elizabeth Bradley, PhD and
- R. Sean Morrison, MD
- ↵*Department of Geriatrics, Mount Sinai School of Medicine, Box 1070, One Gustave Levy Place, New York, New York 10029
We thank Dr. Raphael and colleagues for their interest in our report (1). The investigators report their own findings, which demonstrate that patients with implantable cardioverter-defibrillators have relatively poor understanding of their device as it relates to options for deactivation. Their findings confirm our previous qualitative work with patients as well (2). The investigators point out that if physicians think patients understand options for deactivation, but in reality they do not, then this can be a reason that discussions about deactivation occur so rarely. We are in complete agreement with these investigators and did mention in our original contribution that this apparent incongruity between physician perception of patients' knowledge and what patients' actually understand poses a challenge to communication about deactivation. We thank Dr. Raphael and colleagues for highlighting this important issue in their letter.
- American College of Cardiology Foundation